Evidence map›Paper›PMID 41904744›Full record

ArticleCellular and molecular life sciences : CMLS2026

TRPV4 is involved in NLRP3 and NLRP1 inflammasomes activation after pilocarpine-induced status epilepticus in mice : Concise title: TRPV4-mediated inflammasome activation in epilepsy.

Lihan Liu, Guowen Zhang, Yu Xu, Xiaolin Wang, Sha Sha, Chunfeng Wu, Wei Li, Lei Chen

Abstract read
In one paragraph

Article in Cellular and molecular life sciences : CMLS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lihan LiuDepartment of Physiology, Nanjing Medical University, No. 101, Longmian Ave, Nanjing, Jiangsu Province, 211166, P.R. China.
Guowen ZhangDepartment of Physiology, Nanjing Medical University, No. 101, Longmian Ave, Nanjing, Jiangsu Province, 211166, P.R. China.
Yu XuDepartment of Physiology, Nanjing Medical University, No. 101, Longmian Ave, Nanjing, Jiangsu Province, 211166, P.R. China.
Xiaolin WangDepartment of Physiology, Nanjing Medical University, No. 101, Longmian Ave, Nanjing, Jiangsu Province, 211166, P.R. China.
Sha ShaDepartment of Physiology, Nanjing Medical University, No. 101, Longmian Ave, Nanjing, Jiangsu Province, 211166, P.R. China.
Chunfeng WuDepartment of Neurology, Children's Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, 210009, P.R. China.
Wei LiDepartment of Clinical Research Centre, Children's Hospital of Nanjing Medical University, No. 72, Guangzhou Road, Nanjing, Jiangsu Province, 210009, P.R. China. njchlw@njmu.edu.cn.ORCID http://orcid.org/0000-0003-0769-5805
Lei ChenDepartment of Physiology, Nanjing Medical University, No. 101, Longmian Ave, Nanjing, Jiangsu Province, 211166, P.R. China. chenl@njmu.edu.cn.ORCID http://orcid.org/0000-0002-7382-8306

Funding

National Natural Science Foundation of China 81971274
6 · The paper itself

Abstract

The nucleotide-binding oligomerization domain (NOD)-like receptor family pyrin domain-containing 1 (NLRP1) and NLRP3 inflammasomes are activated in temporal lobe epilepsy (TLE), leading to neuroinflammation, pyroptosis, and neuronal injury. Protein phosphatase 2 A (PP2A) and the toll-like receptor 4 (TLR4)–p38 MAPK signaling pathway participate in regulating these inflammasomes. Although blocking transient receptor potential vanilloid 4 (TRPV4) alleviates inflammation and neuronal damage after pilocarpine-induced status epilepticus (PISE), the underlying mechanisms remain unclear. Here, we found that NLRP1 and NLRP3 expression and activation were markedly increased in the hippocampus during the acute phase post-PISE, accompanied by enhanced pyroptosis and inflammatory responses. Both PP2A activity and TLR4–p38 MAPK signaling were upregulated. Pharmacological inhibition revealed that PP2A primarily drove NLRP3 activation, whereas TLR4–p38 MAPK signaling promoted NLRP1 activation, collectively contributing to pyroptosis and neuronal injury. TRPV4 blockade simultaneously suppressed PP2A activity and TLR4–p38 MAPK signaling, thereby inhibiting NLRP1/NLRP3 inflammasome activation and exerting neuroprotective effects. Conversely, TRPV4 activation with GSK1016790A promoted inflammasome activation, pyroptosis, and activation of PP2A and TLR4–p38 MAPK signaling; these effects were attenuated by inhibiting PP2A or TLR4–p38 MAPK. In HT-22 cells, TRPV4 activation activated the TLR4–p38 MAPK–NLRP1 axis, and NLRP1 knockdown alleviated pyroptosis. Finally, inhibition of TRPV4, PP2A, NLRP3, or NLRP1 markedly reduced seizure frequency and duration in PISE mice. Collectively, these findings suggest that TRPV4 blockade suppresses the PP2A–NLRP3 and TLR4–p38 MAPK–NLRP1 pathways, attenuating neuroinflammation and pyroptosis, and thereby reducing seizure activity during the acute phase following PISE.

Indexed as

Adaptor Proteins, Signal TransducingApoptosis Regulatory ProteinsInflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinStatus EpilepticusTRPV Cation ChannelsAnimalsDisease Models, AnimalHippocampusMaleMiceMice, Inbred C57BLp38 Mitogen-Activated Protein KinasesPilocarpineProtein Phosphatase 2PyroptosisAdaptor Proteins, Signal TransducingApoptosis Regulatory ProteinsInflammasomesNALP1 protein, mouseNLR Family, Pyrin Domain-Containing 3 ProteinNlrp3 protein, mousep38 Mitogen-Activated Protein KinasesPilocarpineProtein Phosphatase 2Toll-Like Receptor 4Trpv4 protein, mouseTRPV Cation ChannelsExperimental epilepsy modelHippocampal pathologyInflammation-related signalingNeuroinflammationSeizure-induced brain injury

Identifiers

PMID41904744
PMCPMC13187113

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.